Re: Novo Nordisk to Begin Phase 3 Studies of Ultra-Rapid-Acting Version of Novolog i

Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BobW

Rank: Vice President [?]

Points: 1080 [?]

Votes: 11 Score: 4.0 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Novo Nordisk to Begin Phase 3 Studies of Ultra-Rapid-Acting Version of Novolog i

in response to

Novo Nordisk to Begin Phase 3 Studies of Ultra-Rapid-Acting Version of Novolog i

brentie98

posted on Mar 17, 2013 04:47PM

Thanks for posting this Brentie.

This kind of development is Mannkind's biggest threat. Fortunately Mannkind is quite a bit ahead in getting to market. Speeding Afrezza's adoption rate is going to be important and another reason that a partnership is so important.

That being said, I think that FIAsp is still injected subcutaneously, so I would expect it to be slower than Afrezza. How does that affect its duration? Any comments?

1 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply